secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0001213900-23-002343
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed Phase 3 oral insulin trial fails; discontinues T2D program
-----------------------------------------------------------------

- Phase 3 ORA-D-013-1 of ORMD-0801 missed primary endpoint: mean A1C change at 26 weeks.
- Secondary endpoint (fasting plasma glucose) also missed; no serious drug-related adverse events.
- Company will discontinue all oral insulin clinical activities for type 2 diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390023002343/0001213900-23-002343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390023002343/ea171576-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-002343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer